FLUOXETINE 20-EXIR
Capsule Fluoxetine 20mg
| Generic Name of Product | Brand Name | Dosage Form | Strength | Pharmacologic Group | Therapeutic Group | Unit Per Pack |
| Fluoxetine | Lorazac® | Capsule | 20 mg | Selective serotonin reuptake inhibitor | Nervous system | 100 |
Indications And Usage |
Lorazac and Olanzapine in Combination: Depressive Episodes Associated with Bipolar I Disorder |
Administration | Major Depressive Disorder: Adult: A dose of 20 mg/day, administered in the morning, is recommended as the initial dose. Pediatric: Treatment should be initiated with a dose of 10 or 20 mg/day. After 1 week at 10 mg/day, the dose should be increased to 20 mg/day. Obsessive Compulsive Disorder: Adult: A dose of 20 mg/day, administered in the morning, is recommended as the initial dose. The full therapeutic effect may be delayed until 5 weeks of treatment or longer. Pediatric: In adolescents and higher weight children, treatment should be initiated with a dose of 10 mg/day. After 2 weeks, the dose should be increased to 20 mg/day. Experience with daily doses greater than 20 mg is very minimal, and there is no experience with doses greater than 60 mg. Bulimia Nervosa: The recommended dose is 60 mg/day, administered in the morning. Panic Disorder: Treatment should be initiated with a dose of 10 mg/day. After one week, the dose should be increased to 20 mg/day. |
Contraindications | Monoamine Oxidase Inhibitors, Pimozide, Thioridazine |
Precautions | Clinical Worsening and Suicide Risk, Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-Like Reactions, Allergic Reactions and Rash, Screening Patients for Bipolar Disorder and Monitoring for Mania/Hypomania, Seizures, Altered Appetite and Weight, Abnormal Bleeding, Hyponatremia, Anxiety and Insomnia, Use in Patients With Concomitant Illness, Potential for Cognitive and Motor Impairment, Long Elimination Half-Life, Discontinuation of Treatment, Lorazac and Olanzapine in Combination |
Adverse Reactions | More common: Hives, itching, or skin rash, inability to sit still, restlessness Less common: Chills or fever, joint or muscle pain |
Pregnancy and lactation | C |
Renal and liver Impairment | Renal impairment: Use caution; drug accumulation may occur with severe renal impairment Hepatic impairment (cirrhosis): Decreased clearance of parent drug and active metabolite (norfluoxetine); lower or less frequent dose recommended |
Laboratory Tests | There are no specific laboratory tests recommended. |
Indications And Usage |
Lorazac and Olanzapine in Combination: Depressive Episodes Associated with Bipolar I Disorder |
Administration | Major Depressive Disorder: Adult: A dose of 20 mg/day, administered in the morning, is recommended as the initial dose. Pediatric: Treatment should be initiated with a dose of 10 or 20 mg/day. After 1 week at 10 mg/day, the dose should be increased to 20 mg/day. Obsessive Compulsive Disorder: Adult: A dose of 20 mg/day, administered in the morning, is recommended as the initial dose. The full therapeutic effect may be delayed until 5 weeks of treatment or longer. Pediatric: In adolescents and higher weight children, treatment should be initiated with a dose of 10 mg/day. After 2 weeks, the dose should be increased to 20 mg/day. Experience with daily doses greater than 20 mg is very minimal, and there is no experience with doses greater than 60 mg. Bulimia Nervosa: The recommended dose is 60 mg/day, administered in the morning. Panic Disorder: Treatment should be initiated with a dose of 10 mg/day. After one week, the dose should be increased to 20 mg/day. |
Contraindications | Monoamine Oxidase Inhibitors, Pimozide, Thioridazine |
Precautions | Clinical Worsening and Suicide Risk, Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-Like Reactions, Allergic Reactions and Rash, Screening Patients for Bipolar Disorder and Monitoring for Mania/Hypomania, Seizures, Altered Appetite and Weight, Abnormal Bleeding, Hyponatremia, Anxiety and Insomnia, Use in Patients With Concomitant Illness, Potential for Cognitive and Motor Impairment, Long Elimination Half-Life, Discontinuation of Treatment, Lorazac and Olanzapine in Combination |
Adverse Reactions | More common: Hives, itching, or skin rash, inability to sit still, restlessness Less common: Chills or fever, joint or muscle pain |
Pregnancy and lactation | C |
Renal and liver Impairment | Renal impairment: Use caution; drug accumulation may occur with severe renal impairment Hepatic impairment (cirrhosis): Decreased clearance of parent drug and active metabolite (norfluoxetine); lower or less frequent dose recommended |
Laboratory Tests | There are no specific laboratory tests recommended. |
Indications And Usage |
Lorazac and Olanzapine in Combination: Depressive Episodes Associated with Bipolar I Disorder |
Administration | Major Depressive Disorder: Adult: A dose of 20 mg/day, administered in the morning, is recommended as the initial dose. Pediatric: Treatment should be initiated with a dose of 10 or 20 mg/day. After 1 week at 10 mg/day, the dose should be increased to 20 mg/day. Obsessive Compulsive Disorder: Adult: A dose of 20 mg/day, administered in the morning, is recommended as the initial dose. The full therapeutic effect may be delayed until 5 weeks of treatment or longer. Pediatric: In adolescents and higher weight children, treatment should be initiated with a dose of 10 mg/day. After 2 weeks, the dose should be increased to 20 mg/day. Experience with daily doses greater than 20 mg is very minimal, and there is no experience with doses greater than 60 mg. Bulimia Nervosa: The recommended dose is 60 mg/day, administered in the morning. Panic Disorder: Treatment should be initiated with a dose of 10 mg/day. After one week, the dose should be increased to 20 mg/day. |
Contraindications | Monoamine Oxidase Inhibitors, Pimozide, Thioridazine |
Precautions | Clinical Worsening and Suicide Risk, Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-Like Reactions, Allergic Reactions and Rash, Screening Patients for Bipolar Disorder and Monitoring for Mania/Hypomania, Seizures, Altered Appetite and Weight, Abnormal Bleeding, Hyponatremia, Anxiety and Insomnia, Use in Patients With Concomitant Illness, Potential for Cognitive and Motor Impairment, Long Elimination Half-Life, Discontinuation of Treatment, Lorazac and Olanzapine in Combination |
Adverse Reactions | More common: Hives, itching, or skin rash, inability to sit still, restlessness Less common: Chills or fever, joint or muscle pain |
Pregnancy and lactation | C |
Renal and liver Impairment | Renal impairment: Use caution; drug accumulation may occur with severe renal impairment Hepatic impairment (cirrhosis): Decreased clearance of parent drug and active metabolite (norfluoxetine); lower or less frequent dose recommended |
Laboratory Tests | There are no specific laboratory tests recommended. |
